Peptide
Contacts
الموردون
البيوتيديات
الخبراء
الأبحاث
تعلم
المجتمع
أخبار
أدوات
Search...
⌘K
تسجيل الدخول
انضم الآن
فتح القائمة
FDA
FDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibility
UPDATE
Semaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025
REGULATORY
12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC review
REGULATORY
No formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027
NEWS
STAT+: Peptide market poised to explode with new Hims and Noom launches
RESEARCH
Alleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]
RESEARCH
Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]
RESEARCH
SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]
RESEARCH
Semaglutide in Alcohol Use Disorder [NCT07949474]
RESEARCH
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]
RESEARCH
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]
NEWS
‘Selling and marketing snake oil’: The debate over compounded GLP-1s
RESEARCH
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD [NCT07527910]
RESEARCH
Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008) [NCT07756359]
FDA
FDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibility
UPDATE
Semaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025
REGULATORY
12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC review
REGULATORY
No formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027
NEWS
STAT+: Peptide market poised to explode with new Hims and Noom launches
RESEARCH
Alleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]
RESEARCH
Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]
RESEARCH
SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]
RESEARCH
Semaglutide in Alcohol Use Disorder [NCT07949474]
RESEARCH
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]
RESEARCH
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]
NEWS
‘Selling and marketing snake oil’: The debate over compounded GLP-1s
RESEARCH
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD [NCT07527910]
RESEARCH
Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008) [NCT07756359]
For research purposes only.
Full disclaimer →
Loading...